Exosomes Derived from MiR-122-modified Adipose Tissue-derived MSCs Increase Chemosensitivity of Hepatocellular Carcinoma

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2015 Oct 31

PMID 26514126

Citations 376

Authors

Guohua Lou

Xiuli Song

Fan Yang

Shanshan Wu

Jing Wang

Zhi Chen

Yanning Liu

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) displays high resistance to conventional chemotherapy. Considering that microRNA-122 (miR-122) performs an essential function to promote chemosensitivity of HCC cells, an effective vehicle-mediated miR-122 delivery may represent a promising strategy for HCC chemotherapy. An increasing interest is focused on the use of exosomes as biological vehicles for microRNAs (miRNA) transfer. Mesenchymal stem cells (MSCs) are known for their capacity to produce large amounts of exosomes. This study aimed to determine whether adipose tissue-derived MSC (AMSC) exosomes can be used for miR-122 delivery.

Methods: AMSCs were transfected with a miR-122 expression plasmid. At 48 h after transfection, AMSC-derived exosomes (122-Exo) were harvested and added to recipient HCC cells. Expression levels of miR-122 in AMSCs, exosomes, and HCC cells were quantified by real-time PCR. The mRNA and protein levels of miR-122-target genes in recipient HCC cells were quantified by real-time PCR and Western blot, respectively. The effects of 122-Exo on cell viability, apoptosis, and cell cycle of HCC cells were evaluated by MTT and flow cytometry analysis. Xenograft models were used to determine whether 122-Exo can sensitize HCC cells to sorafenib in vivo.

Results: Data showed that miR-122-transfected AMSC can effectively package miR-122 into secreted exosomes, which can mediate miR-122 communication between AMSCs and HCC cells, thereby rendering cancer cells sensitive to chemotherapeutic agents through alteration of miR-122-target gene expression in HCC cells. Moreover, intra-tumor injection of 122-Exo significantly increased the antitumor efficacy of sorafenib on HCC in vivo.

Conclusions: The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to enhance HCC chemosensitivity.

Citing Articles

Engineered exosomes restore miR-508-5p expression in uterine corpus endometrial carcinoma and reduce tumor progression and metastasis by targeting DLL3.

Li Y, Liu H, Feng J, Tian W, Du J, Zhang L Front Oncol. 2025; 15:1532564.

PMID: 40066092 PMC: 11891050. DOI: 10.3389/fonc.2025.1532564.

An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma.

Zhao M, Li Q, Chai Y, Rong R, He L, Zhang Y J Nanobiotechnology. 2025; 23(1):173.

PMID: 40045315 PMC: 11881385. DOI: 10.1186/s12951-025-03238-9.

Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.

Balaraman A, Babu M, Afzal M, Sanghvi G, M M R, Gupta S Regen Ther. 2025; 28:558-572.

PMID: 40034540 PMC: 11872554. DOI: 10.1016/j.reth.2025.01.019.

Extracellular vesicle-mediated gene therapy targets BRAF-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway.

Wang D, Wang L, Zhang W, Xu K, Chen L, Guo Z J Nanobiotechnology. 2025; 23(1):129.

PMID: 39979881 PMC: 11843959. DOI: 10.1186/s12951-025-03205-4.

Risk factors of primary liver cancer initiation associated with tumour initiating cell emergence: novel targets for promising preventive therapies.

Brouillet A, Lafdil F eGastroenterology. 2025; 1(1):e100010.

PMID: 39944247 PMC: 11770463. DOI: 10.1136/egastro-2023-100010.

References

Ou D, Lee B, Chang Y, Lin L, Liou J, Hsu C . Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway. PLoS One. 2013; 8(6):e66589. PMC: 3688529. DOI: 10.1371/journal.pone.0066589. View

Roccaro A, Sacco A, Maiso P, Azab A, Tai Y, Reagan M . BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123(4):1542-55. PMC: 3613927. DOI: 10.1172/JCI66517. View

Tian Y, Li S, Song J, Ji T, Zhu M, Anderson G . A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2013; 35(7):2383-90. DOI: 10.1016/j.biomaterials.2013.11.083. View

Wu J, Zhu A . Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011; 4:30. PMC: 3141798. DOI: 10.1186/1756-8722-4-30. View

Hu G, Drescher K, Chen X . Exosomal miRNAs: Biological Properties and Therapeutic Potential. Front Genet. 2012; 3:56. PMC: 3330238. DOI: 10.3389/fgene.2012.00056. View

Lai R, Arslan F, Lee M, Sze N, Choo A, Chen T . Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010; 4(3):214-22. DOI: 10.1016/j.scr.2009.12.003. View

Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y . Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013; 6:37. PMC: 3693878. DOI: 10.1186/1756-8722-6-37. View

Fan S, Chen W, Lv X, Tang Q, Sun L, Liu B . miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. Cancer Lett. 2015; 362(2):183-91. DOI: 10.1016/j.canlet.2015.03.045. View

Sun Z, Wang S, Zhao R . The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 2014; 7:14. PMC: 3943443. DOI: 10.1186/1756-8722-7-14. View

10.

Bandiera S, Pfeffer S, Baumert T, Zeisel M . miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2014; 62(2):448-57. DOI: 10.1016/j.jhep.2014.10.004. View

11.

Zhang K, Zhang Q, Zhang Q, Sun H, Ao J, Chai Z . Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014; 7:28. PMC: 4022144. DOI: 10.1186/1756-8722-7-28. View

12.

Bai S, Nasser M, Wang B, Hsu S, Datta J, Kutay H . MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009; 284(46):32015-27. PMC: 2797273. DOI: 10.1074/jbc.M109.016774. View

13.

Yang C, Jiang F, Xu F, Jiang G . ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol. 2012; 33(5):1535-41. DOI: 10.1007/s13277-012-0405-4. View

14.

Ullah M, Stich S, Notter M, Eucker J, Sittinger M, Ringe J . Transdifferentiation of mesenchymal stem cells-derived adipogenic-differentiated cells into osteogenic- or chondrogenic-differentiated cells proceeds via dedifferentiation and have a correlation with cell cycle arresting and driving genes. Differentiation. 2013; 85(3):78-90. DOI: 10.1016/j.diff.2013.02.001. View

15.

Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W . Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015; 8:83. PMC: 4496882. DOI: 10.1186/s13045-015-0181-x. View

16.

Kumar D, Gupta D, Shankar S, Srivastava R . Biomolecular characterization of exosomes released from cancer stem cells: Possible implications for biomarker and treatment of cancer. Oncotarget. 2015; 6(5):3280-91. PMC: 4413653. DOI: 10.18632/oncotarget.2462. View

17.

Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y . Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 2011; 315(1):28-37. DOI: 10.1016/j.canlet.2011.10.002. View

18.

Sarkar F, Li Y, Wang Z, Kong D, Ali S . Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010; 13(3):57-66. PMC: 2883024. DOI: 10.1016/j.drup.2010.02.001. View

19.

Wang W, Chen Y . Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014; 7:86. PMC: 4269921. DOI: 10.1186/s13045-014-0086-0. View

20.

Yeo R, Lai R, Zhang B, Tan S, Yin Y, Teh B . Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2012; 65(3):336-41. DOI: 10.1016/j.addr.2012.07.001. View